Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

48.12 +1.03 (+2.19%)
Streaming Delayed Price Updated: 12:40 PM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
35 36 Next >
News headline image
3 Smart Stocks to Buy if a Recession Is on the Way ↗
Their products will enjoy strong demand regardless of what happens with the economy. 
Via The Motley Fool
News headline image
CRISPR Therapeutics Stock: Bull vs. Bear ↗
Should investors buy this risky biotech stock as the company moves toward bringing its first major treatment to market? 
Via The Motley Fool
News headline image
7 Biotech Stocks That Will Make You Rich in 10 Years ↗
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years. 
Via InvestorPlace
News headline image
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years ↗
CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in 10 years. 
Via InvestorPlace
News headline image
5 Reasons to Buy Vertex Pharmaceuticals Now ↗
Vertex shares are extending last year's gains, and that trend probably isn't over. 
Via The Motley Fool
News headline image
2 Stocks Down More Than 25% to Buy Right Now ↗
These companies are set for a new era of growth. 
Via The Motley Fool
News headline image
Is It Too Late to Buy Vertex Pharmaceuticals Stock? ↗
Vertex is heading for a new phase of growth. 
Via The Motley Fool
Expert Ratings for CRISPR Therapeutics ↗
 
Via Benzinga
News headline image
5 Potentially Explosive Stocks to Buy in 2023 ↗
These stocks all dropped in the double digits last year. But their future prospects are brilliant. 
Via The Motley Fool
News headline image
More Likely to 5X First: CRISPR Therapeutics vs. InMode ↗
These two companies are in very different situations but could generate significant returns for investors. 
Via The Motley Fool
News headline image
2 Growth Stocks You May Regret not Buying Right Now ↗
At their beaten-down valuations, these stocks have the potential to deliver some impressive returns. 
Via The Motley Fool
News headline image
Can Cathie Wood Bounce Back in 2023? ↗
Wood sticks by her strategy, no matter what the general market does. 
Via The Motley Fool
News headline image
2 Supercharged Stocks to Buy Right Now That Could Soar in 2023 ↗
These stocks have been solid performers despite the macroeconomic uncertainties in 2022. 
Via The Motley Fool
News headline image
2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years ↗
Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow. 
Via The Motley Fool
News headline image
2 Under-the-Radar Biotech Stocks to Buy in 2023 ↗
These biotechnology stocks are pushing ahead with promising innovations. 
Via The Motley Fool
News headline image
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
News headline image
Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away' ↗
Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams. 
Via Benzinga
News headline image
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Rich Over Time ↗
Wood is bargain hunting now. And these buys may pay off big in the long run. 
Via The Motley Fool
News headline image
3 Growth Stocks That Could Skyrocket 50% or More In 2023, According to Wall Street ↗
These stocks fell significantly in 2022. But analysts expect that huge rebounds could be on the way in the new year. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗
 
Via Benzinga
News headline image
1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now) ↗
Both stocks have fallen brutally this year, but only one has a chance to recover soon. 
Via The Motley Fool
News headline image
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond ↗
These two biotechs are flying high right now. 
Via The Motley Fool
News headline image
5 Unstoppable Trends to Invest $5,000 in for 2023 ↗
These trends won't fade away, and some of the companies that are positioned to ride them should be big winners. 
Via The Motley Fool
News headline image
Could CRISPR Therapeutics Help You Become a Millionaire? ↗
The gene-editing stock still has plenty of promise. 
Via The Motley Fool
News headline image
Is Vertex Pharmaceuticals a Buy? ↗
There's more growth ahead for this biotech giant. 
Via The Motley Fool
News headline image
After Doubling in the Past 6 Months, Is This Stock a Buy? ↗
This company has had a solid year, but there is still plenty of work ahead. 
Via The Motley Fool
News headline image
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023? ↗
Crispr and Vertex are working toward the first submissions for a CRISPR-based product. 
Via Investor's Business Daily
News headline image
2 No-Brainer Biotech Stocks to Buy Right Now ↗
Vertex Therapeutics and Amgen have the building blocks for long-term success. 
Via The Motley Fool
News headline image
3 Cathie Wood Stocks That Could Make Big Comebacks in 2023 ↗
These businesses aren't in as much trouble as their stock returns suggest that they are. 
Via The Motley Fool
News headline image
3 Growth Stocks That Are Screaming Buys in December ↗
Don't let these companies pass you by the next time you go stock shopping. 
Via The Motley Fool
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.